000182308 001__ 182308
000182308 005__ 20240229145715.0
000182308 0247_ $$2doi$$a10.3390/cancers14205069
000182308 0247_ $$2pmid$$apmid:36291853
000182308 0247_ $$2altmetric$$aaltmetric:137559410
000182308 037__ $$aDKFZ-2022-02565
000182308 041__ $$aEnglish
000182308 082__ $$a610
000182308 1001_ $$0P:(DE-HGF)0$$aKirste, Simon$$b0
000182308 245__ $$aStereotactic Body Radiotherapy for Renal Cell Carcinoma in Patients with Von Hippel-Lindau Disease-Results of a Prospective Trial.
000182308 260__ $$aBasel$$bMDPI$$c2022
000182308 3367_ $$2DRIVER$$aarticle
000182308 3367_ $$2DataCite$$aOutput Types/Journal article
000182308 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1674637744_13517
000182308 3367_ $$2BibTeX$$aARTICLE
000182308 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000182308 3367_ $$00$$2EndNote$$aJournal Article
000182308 520__ $$aVon Hippel-Lindau disease (VHL) is a hereditary disorder associated with malignant tumors including clear cell renal cell carcinoma (ccRCC). Partial nephrectomy is complicated by multilocular tumor occurrence and a high recurrence rate. The aim of this study was to evaluate the potential of stereotactic body radiotherapy (SBRT) as an alternative treatment approach in VHL patients with multiple ccRCC. Patients with VHL and a diagnosis of ccRCC were enrolled. SBRT was conducted using five fractions of 10 Gy or eight fractions of 7.5 Gy. The primary endpoint was local control (LC). Secondary endpoints included alteration of renal function and adverse events. Seven patients with a total of eight treated lesions were enrolled. Median age was 44 years. Five patients exhibited multiple bilateral kidney cysts in addition to ccRCC. Three patients underwent at least one partial nephrectomy in the past. After a median follow-up of 43 months, 2-year LC was 100%, while 2-year CSS, 2-year PFS and 2-year OS was 100%, 85.7% and 85.7%, respectively. SBRT was very well tolerated with no acute or chronic toxicities grade ≥ 2. Mean estimated glomerular filtration rate (eGFR) at baseline was 83.7 ± 13.0 mL/min/1.73 m2, which decreased to 76.6 ± 8.0 mL/min/1.73 m2 after 1 year. Although the sample size was small, SBRT resulted in an excellent LC rate and was very well tolerated with preservation of kidney function in patients with multiple renal lesions and cysts.
000182308 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000182308 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000182308 650_7 $$2Other$$aSABR
000182308 650_7 $$2Other$$aSBRT
000182308 650_7 $$2Other$$arenal cell carcinoma
000182308 650_7 $$2Other$$astereotactic ablative radiotherapy
000182308 650_7 $$2Other$$astereotactic body radiotherapy
000182308 650_7 $$2Other$$avon Hippel–Lindau disease
000182308 7001_ $$0P:(DE-He78)80e100a16534f5fc67f7436ee67a47f9$$aRühle, Alexander$$b1$$udkfz
000182308 7001_ $$aZschiedrich, Stefan$$b2
000182308 7001_ $$aSchultze-Seemann, Wolfgang$$b3
000182308 7001_ $$aJilg, Cordula A$$b4
000182308 7001_ $$aNeumann-Haefelin, Elke$$b5
000182308 7001_ $$aLo, Simon S$$b6
000182308 7001_ $$0P:(DE-HGF)0$$aGrosu, Anca-Ligia$$b7
000182308 7001_ $$0P:(DE-HGF)0$$aKim, Emily$$b8
000182308 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers14205069$$gVol. 14, no. 20, p. 5069 -$$n20$$p5069$$tCancers$$v14$$x2072-6694$$y2022
000182308 909CO $$ooai:inrepo02.dkfz.de:182308$$pVDB
000182308 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000182308 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)80e100a16534f5fc67f7436ee67a47f9$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000182308 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000182308 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000182308 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000182308 9141_ $$y2022
000182308 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-04
000182308 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000182308 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-05-04
000182308 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000182308 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000182308 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000182308 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2021$$d2022-11-30
000182308 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-30
000182308 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-30
000182308 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-01-24T07:56:58Z
000182308 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-01-24T07:56:58Z
000182308 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2022-01-24T07:56:58Z
000182308 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-30
000182308 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-30
000182308 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-30
000182308 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-30
000182308 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-30
000182308 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2021$$d2022-11-30
000182308 9201_ $$0I:(DE-He78)FR01-20160331$$kFR01$$lDKTK FR zentral$$x0
000182308 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x1
000182308 980__ $$ajournal
000182308 980__ $$aVDB
000182308 980__ $$aI:(DE-He78)FR01-20160331
000182308 980__ $$aI:(DE-He78)E055-20160331
000182308 980__ $$aUNRESTRICTED